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Abstract
Background: Numerous metabolic pathways have been implicated in diabetes-induced renal injury, yet few studies have
utilized unbiased systems biology approaches for mapping the interconnectivity of diabetes-dysregulated proteins that are
involved. We utilized a global, quantitative, differential proteomic approach to identify a novel retinoic acid hub in renal
cortical protein networks dysregulated by type 2 diabetes.
Methodology/Principal Findings: Total proteins were extracted from renal cortex of control and db/db mice at 20 weeks of
age (after 12 weeks of hyperglycemia in the diabetic mice). Following trypsinization,
18O- and
16O-labeled control and
diabetic peptides, respectively, were pooled and separated by two dimensional liquid chromatography (strong cation
exchange creating 60 fractions further separated by nano-HPLC), followed by peptide identification and quantification using
mass spectrometry. Proteomic analysis identified 53 proteins with fold change $1.5 and p#0.05 after Benjamini-Hochberg
adjustment (out of 1,806 proteins identified), including alcohol dehydrogenase (ADH) and retinaldehyde dehydrogenase
(RALDH1/ALDH1A1). Ingenuity Pathway Analysis identified altered retinoic acid as a key signaling hub that was altered in
the diabetic renal cortical proteome. Western blotting and real-time PCR confirmed diabetes-induced upregulation of
RALDH1, which was localized by immunofluorescence predominantly to the proximal tubule in the diabetic renal cortex,
while PCR confirmed the downregulation of ADH identified with mass spectrometry. Despite increased renal cortical tissue
levels of retinol and RALDH1 in db/db versus control mice, all-trans-retinoic acid was significantly decreased in association
with a significant decrease in PPARb/d mRNA.
Conclusions/Significance: Our results indicate that retinoic acid metabolism is significantly dysregulated in diabetic kidneys,
and suggest that a shift in all-trans-retinoic acid metabolism is a novel feature in type 2 diabetic renal disease. Our observations
provide novel insights into potential links between altered lipid metabolism and other gene networks controlled by retinoic acid
in the diabetic kidney, and demonstrate the utility of using systems biology to gain new insights into diabetic nephropathy.
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Introduction
Diabetic nephropathy has become the most common cause of
end-stage renal failure in the western world and its incidence
continues to increase despite our understanding of the importance
of microalbuminuria, glycemic control and blood pressure
reduction. Many diabetic patients progress to end-stage renal
disease despite recent advances in available therapeutics [1].
Numerous biochemical and metabolic pathways have emerged as
predominant pathophysiological mechanisms for diabetes-induced
renal injury [2–11]. The importance of each of these pathways is
supported by a large volume of experimental animal data, and in
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proposed biochemical mechanism. It is noteworthy that all of
these proposed mechanisms involve dysregulated proteins. While
there are probably numerous points of crosstalk between these
different protein pathways, reductionist strategies are inherently
unlikely to identify these interconnections. Only a systems biology
approach can integrate the numerous proteins that are involved
into higher-order cassettes operating within diabetic cells and
tissues [12,13], but few studies of diabetic complications have
utilized this unbiased, global approach for mapping the inter-
connectivity of the different proteins postulated to have a causal
role in diabetic nephropathy.
Using such an approach, we have identified previously
unrecognized alterations in vitamin A metabolism as an important
hub in protein networks dysregulated by diabetes in the renal
cortex of type 2 diabetic mice. Vitamin A (retinol) functions in
gene regulation for growth and development [14,15]. These
functions are regulated by numerous enzymes controlling a two
step enzymatic reaction in which retinol is reversibly oxidized to
bioactive retinaldehyde (retinal) followed by irreversible oxidation
to the carboxylic acid, retinoic acid. Retinol is transported in the
plasma via retinol binding protein (RBP), which essentially makes
retinol available to all cells containing the intracellular lipid
binding protein, cellular retinol binding protein (CRBP), which in
turn, facilitates uptake of retinol into cells as well as its metabolism
into retinyl esters or retinoic acid [16]. Elevated plasma levels of
RBP4 have been implicated in the development of the metabolic
syndrome and insulin resistance, and have been inversely
correlated with adipocyte glucose transporter 4 (GLUT4) protein
levels [17]. This metabolic pathway regulates gene expression via
the carboxylic acid isomer, all-trans-retinoic acid (atRA) that is a
ligand for two families of retinoid receptors – retinoic acid
receptors (RAR) and retinoid X receptors (RXR). Although 9-cis-
retinoic acid does serve as a pharmacological ligand for RXR and
RAR, it has not been detected in vivo with rigorous analytical
assays [18].
Despite a vast body of literature describing a role for retinoic
acid as a critical regulator of gene expression modulating
embryonic development and adult tissue regeneration, immune
function, development, metabolism, and inflammation in multiple
organ systems, little is known about the role of altered retinoic acid
metabolism in diabetes, including diabetic nephropathy. Previ-
ously, changes in plasma levels of retinoids have been associated
with type 1 diabetes, cardiovascular risk and cancer risk. A
protective role of atRA has been shown in diabetic and
nondiabetic proteinuric diseases [19], and a link between a
cytochrome P450 enzyme (2E1) known to metabolize atRA and
increased mitochondrial oxidative stress in type 1 diabetic rat
kidneys has been established [20,21]. Recently, atRA has been
shown to bind PPARb/d and act as a ligand to activate
transcription, suggesting that altered retinoic metabolism could
provide a potential link to insulin resistance and fatty acid
metabolism [22]. This has recently been demonstrated in mice fed
high-fat diets [23]. Since others have reported that atRA failed to
induce transcriptional activity of PPARb/d using reporter gene
assays [24], this remains controversial. We report here that an
enzyme involved in retinoic acid metabolism – RALDH1 (P24549;
EC=1.2.1.36) – is dysregulated in the renal cortex of 20 week-old
db/db mice, a well characterized and widely used model of type 2
diabetes with consistent and relatively robust albuminuria
(reflecting functional changes) and mesangial expansion, increased
glomerular surface area, and tubulo-interstitial changes (reflecting
early structural changes). Changes in RALDH1 are correlated
with significant decreases in renal cortical levels of atRA and
PPARb/d message despite elevated plasma levels of retinol and
atRA. We also report that ADH1 (P00329; EC=1.1.1.1) is
dysregulated, although its role in physiological retinol metabolism
remains controversial.
Methods
Animal and surgical protocols
Male Lepr
db (db/db) and age- and sex-matched control mice
with the same genetic background (C57BLKS/J) were purchased
from Jackson Labs (Bar Harbor, Maine) at 4 weeks of age, and
were housed 2–3/cage in a sterile environment, in a room with a
12 hour light cycle and free access to standard chow and water.
Body weight and nonfasting blood glucose were measured weekly.
Mice were sacrificed 12 weeks after the onset of hyperglycemia,
defined as a group mean value of 15 mmol/L, which occurred
around 8 weeks of age. Age at the time of sacrifice was 20 weeks,
representing a time point when albuminuria, mesangial expansion,
increased glomerular surface area, and tubulo-interstitial changes
are manifested [25]. In addition, significant renal cortical
inflammation, reflecting induction of numerous NF-kB-regulated
cytokines and chemokines, is present at this age [26]. Mice were
anesthetized (ketamine/xylazine; 70/10 mg/kg i.p.), anticoagulat-
ed (5 units heparin), then exsanguinated prior to rapid aortic
perfusion with ice-cold PBS to quickly rinse kidneys free of blood
and to deliver protease and phosphatase inhibitors as described
[26]. Both kidneys were removed, decapsulated, flash-frozen in
liquid nitrogen, then stored at 280uC until processed. Prior to
freezing, a 3–4 mm thick, coronal section through the middle of
the kidney at the level of the renal pelvis was placed in 4%
paraformaldehyde for 24 hours, and then transferred to Hanks
Balanced Salt Solution (HBSS) for storage at 4uC until processed
for immunohistochemistry.
Ethics Statement
Animals were housed in the UTMB Animal Resource Center
and used in accordance with its IACUC policies and the Public
Health Service Guide for the Care and Use of Laboratory
Animals.
Tissue processing, protein extraction and tryptic
digestion
Cortical tissue was separated from the medullary portion of each
kidney under magnification with a dissecting microscope and
s u s p e n d e di n2 0f o l de x c e s s( w t / v o l )o fT R I z o l H reagent (Invitrogen,
Carlsbad, CA). The tissue was homogenized in a 1 ml Dounce
homogenizer on ice. Proteins were extracted from the lysate
according to the manufacturer’s instructions, and the protein pellet
was dissolved in 250 ml of 8 M guanidinium hydrochloride. In each
experimental group, 300 mg of protein from each of five control mice
or 5 diabetic mice were pooled, and the two pools containing 1.5 mg
of protein were reduced with 10 mM dithiothreitol (DTT) for 30 min
at room temperature. Protein cysteinyl residues were alkylated with
30 mMiodoacetamide for2 hat 37uC.Eachsamplewasdiluted106
with 100 mM ammonium bicarbonate, digested with 40 mgo f
trypsin overnight at 37uC, and each tryptic peptide mixture was
desalted with a Sep-PakH C18 cartridge (Waters, Milford, MA)
following the manufacturer’s instructions. Peptides were eluted from
the cartridge with 80% acetonitrile and completely dried using a
Speedvac.
Post-proteolysis
18O-labeling
The
18O-labeling was performed as described [27] with slight
modifications. The dried peptide samples were redissolved with
Retinoic Acid in Diabetes
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(Applied Biosystems, CA) and 200 ml of normal water (H2
16O) or
H2
18O containing 50 mM ammonium bicarbonate were added to
the diabetic and control peptides, respectively, and both samples
were incubated for 48 h at 37uC. Supernatants were collected
using a spin column, and the corresponding
18O- and
16O-labeled
samples were pooled and dried with a Speedvac. The
18O-/
16O-
labeled peptide mixture was desalted using a Sep-PakHC18
cartridge (Waters Corp., Milford, MA) following the manufactur-
er’s instructions; peptides were eluted from the cartridge with 80%
acetonitrile and dried.
Dried peptide pools were redissolved by adding 20 mlo f
acetonitrile and diluted with 100 ml of 5 mM ammonium formate,
pH 2.7. The pooled mixture was loaded onto a strong cation
exchange (SCX) column (4.6 mm625 cm; Poly LC, Columbia,
MD) and separated with a linear gradient from 100% buffer A
(5 mM ammonium formate-20% acetonitrile, pH 2.7) to 25%
buffer B (1 M ammonium formate-20% acetonitrile, pH 3.0) over
40 min at a flow rate of 0.8 ml/min and followed by a linear
gradient from 25% buffer B to 60% buffer B over 20 min. The
eluate was manually collected after the first salt gradient was
started. Sixty fractions, corresponding to 0.8 ml each, were
collected and dried using a Speedvac.
Two-dimensional liquid chromatography - tandem mass
spectrometry (2D LC-MS/MS)
Each SCX fraction was redissolved in 20 ml of 0.1%
trifluorocetic acid (TFA) and was injected onto a C18 peptide
trap (Agilent, Santa Clara, CA), desalted with 0.2% formic acid at
a flow rate of 10 ml/min for 180 min. Peptides were eluted from
the trap and separated on a reversed phase nano-HPLC column
(PicoFritTM, 75 mm610 cm; tip ID 15 mm) with a linear gradient
of 0–50% mobile phase B (0.1% formic acid - 90% acetonitrile) in
mobile phase A (0.1% formic acid) over 120 min at 200 nl/min.
LC-MS/MS experiments were performed with a LTQ linear ion
trap mass spectrometer (ThermoFinnigan, San Jose, CA) equipped
with a nanospray source; the mass spectrometer was coupled on-
line to a ProteomXH nano-HPLC system (ThermoFinnigan, San
Jose, CA). The mass spectrometer was operated in the data-
dependent mode using Xcalibur software. The three most intense
ions in each MS survey scan were automatically selected for
Zoomscan and MS/MS.
Data pre-processing
The acquired MS/MS spectra were searched with SEQUEST
algorithm against a composite target-decoy mouse protein
database consisting of the protein sequences (target) downloaded
from SWISSPROT mouse protein database (downloaded July
2006) and reversed versions of these sequences (decoy) as described
[28]. All SEQUEST searches were performed on the Bioworks 3.2
platform (ThermoFinnigan, San Jose, CA) using the following
parameters: fully tryptic peptide (both tryptic terminus for all
peptides), a mass tolerance of 62.0 Da for precursor ion and 61.0
Da for fragment ion. The output data from these searches were
filtered and sorted by the DTASelect software [29] as previously
described [28]. Only the top one peptide sequence match to each
acquired MS/MS spectrum was considered. The criteria used in
DTASelect were as follows: First, relatively conservative criteria
(Sp$300; DCn$0.12; Xcorr of 1.9, 2.0 and 3.0 for data from a
singly, doubly or triply charged precursor ions, respectively) were
applied. Second, proteins that passed these thresholds were
separated into two groups: proteins identified with two or more
peptides and proteins identified with one peptide. Third, since the
majority of the false positive identifications in our dataset were
within the group of proteins with one identified peptide, much
stricter criteria (Xcorr 2.2, 3.2, or 3.75 for precursor charge states
of 1+,2 +,o r3 +, respectively) were applied to the peptide hits in
this group to increase identification certainty. Fourth, if multiple
spectra were identified to match precisely the same sequence and
charge state, only the spectrum with the highest Xcorr was
retained. Finally, proteins that shared all matched peptides with
other (homologous) proteins were removed. The false discovery
rate (FDR) of identification was calculated to be less than 1% as
described [30].
Quantification of Differential Expression
The abundance ratios of
18O/
16O-labeled peptide pairs were
calculated with in-house software using the following equation [31]:
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where I0, I2 and I4 are the measured relative peak intensities for the
monoisotope peak for an unlabeled peptide, the peak with masses 2
Da higher, and the peak with 4 Da higher masses, respectively; M0,
M2,a n dM4 are the theoretical relative intensities for monoisotopic
peak of the unlabeled peptide, the peaks with masses 2 Da and 4 Da
higher than the monoisotopic peak, respectively. The ‘‘M values’’
were calculated based on the elemental composition of the peptide by
using MS-isotope pattern calculator (http://prospector.ucsf.edu). If a
peptide was identified more than once, a mean and standard
deviation were calculated. The peptide ratios were averaged for all
peptides for each protein to give a ratio per protein.
Data and Statistical Analysis
16O/
18Or a t i o st h a tw e r e#0o r$50 and UniProt identifica-
tions containing less than 5 individual peptide measurements
were removed from further analysis. Calculated ratios were
inverted (to generate a diabetes/control ratio) and log2 trans-
formed prior to calculating mean, standard deviation and p-
values by independent one-sample t-tests. Benjamini-Hochberg
corrections for multiple testing comparisons were performed as
indicated [32]. Data were analyzed through the use of Ingenuity
Pathways Analysis (Ingenuity SystemsH) with a fold change of
$1.5 and p#0.05 with Benjamini-Hochberg correction for
multiple testing.
Immunoblotting
Renal cortex (,50 mg) was homogenized on ice using
Wheaton 1 ml Dounce homogenizers in a 20-fold excess [wt/
vol] of tissue extract buffer [50 mM HEPES (pH 7.0), 10 mM
potassium chloride, 1 mM EDTA, 1 mM EGTA, protease
inhibitor cocktail (Sigma P8340), phosphatase inhibitors (1 mM
orthovanadate and 30 mM sodium fluoride), 1 mM DTT, and
0.5 mM PMSF]. Tissue lysates were electrophoresed on 10%
SDS-polyacrylamide gels and analyzed by immunoblotting after
transfer to nitrocellulose membranes (Bio-Rad Laboratories,
Hercules, CA), using primary antibodies according to each
manufacturer’s instructions, followed by species-specific second-
ary antibodies tagged with a fluorescent dye (IR Dye
TM 800;
Rockland) at a 1:5,000 dilution. Densitometric quantification of
each protein was performed using the LI-COR Bioscience
Odyssey
TM Imaging System (LI-COR Bioscience, Lincoln, NE)
as described [26]. b-actin was measured on every blot for
evaluation of protein loading.
Retinoic Acid in Diabetes
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From each mouse, renal cortical tissue was suspended in 20 fold
excess (wt/vol) of TRIzolH reagent (Invitrogen, Carlsbad, CA),
homogenized in a 1 ml Dounce homogenizer on ice, and RNA
extracted according to the manufacturer’s instructions. cDNA was
synthesized from 5 mg of mRNA using Superscript III (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.
Relative quantification of select mRNA was performed on 1 ml
of cDNA using a MyiQ Single-Color Real-Time PCR Detection
System and iQ SYBR Green Supermix (Bio-Rad Laboratories,
Hercules, CA) according to the manufacturer’s instructions. All
primers were purchased from SABiosciences, Inc (Frederick, MD).
Data were analyzed using the DCT method in reference to
cyclophilin (for RALDH1 and ADH) or GAPDH [33].
Measurement of retinoids
Tissue and plasma samples were collected and handled under
yellow lights. Tissue samples were homogenized by hand in
ground glass homogenizers (Kontes, size 22) on ice in 1.0 to 2.0 ml
saline (0.9% NaCl). Tissue and plasma samples were extracted as
described [18,34,35]. Retinoic acid was quantified by LC/MS/
MS with atmospheric pressure chemical ionization (APCI) in
positive ion mode on an API-4000 (Applied Biosystems) as
described [18,34]. Retinol and retinyl ester were quantified by
HPLC/UV on an Alliance 2690 (Waters) as described [35]. Tissue
retinoids are expressed as mol/g tissue and plasma retinoids are
expressed as mol/ml plasma.
Immunofluorescent Imaging
Paraffin-embedded 5-mm coronal sections through the mid-line
of the kidney at the level of the renal pelvis were washed in xylene
twice for 5 min each, rehydrated by successive rinsing in 100, 95,
75, and 50% ethanol followed by phosphate-buffered saline (PBS),
and antigen retrieval was performed using 10 mmol/l sodium
citrate (pH 6.0) with 0.1% Triton X for 20 min at 95uC. Slides
were blocked using nonimmune sera from the secondary antibody
species diluted to 2% in PBS containing 0.2% cold fish skin
gelatin, 0.1% saponin, and 0.05% Tween 20 for 2 h at room
temperature. Primary antibody directed against RALDH1 (1:200
dilution; Novus Biologicals) was incubated overnight at 4uCi n
blocking buffer containing 2% bovine serum albumin substituted
for the nonimmune sera. Tissue sections were washed three times
in PBS for 10 min each, and secondary antibody (labeled with IR
Dye
TM 680 for Li-COR imaging and AlexaFluor 633 (Molecular
Probes) for confocal microscopy imaging) was added for 2 h at
room temperature. Images were obtained on a Li-COR Bioscience
Odyssey
TM Imaging System (low magnification) and a Zeiss LSM
510 UV META Laser Scanning Confocal Microscope (high
magnification). Negative controls included omitting the primary
antibody.
Statistical analysis
Statistical analysis of the proteomics data was detailed above.
For all other data, the variance was reported as either standard
deviations or standard errors of the mean, and indicated in the
legends for each Table and Figure. Student’s t-test with unequal
variance was used to calculate significance of diabetic to control
comparisons.
Results
Body weights and blood sugar data
Body weights of db/db mice were increased significantly at the
onset of hyperglycemia (,8 weeks of age), peaked by 12 weeks of age
(,2foldincreaseoverage-matchedcontrols),thenremainedconstant
over the next two months (Table 1). After 3 months of hyperglycemia
(20 weeks of age), the db/db mice exhibited significantly elevated non-
fasted blood glucose levels. We have previously demonstrated
persistent hypercholesterolemia, hyperinsulinemia, hyperleptinemia,
and elevated plasma amylin levels in db/db vs control mice with this
age and duration of hyperglycemia [26].
Diabetes-dysregulated renal cortical proteome
Each SCX fraction was submitted for mass spectrometry analysis
three separate times, generating over 880,000 MS/MS spectra that
were used for database searching with the SEQUEST algorithm. A
total of 30,117 peptides were identified with #1% FDR and were
mapped to 1,806 proteins, of which 796 proteins (44%) were
identified with 5 or more peptides. Only these proteins were used for
subsequent statistical and bioinformatics analyses. Table S1 lists the
complete peptide data set for this experiment, while Table S2 lists the
UniProt accession number, gene name, number of peptides used in
the protein identification, mean fold change score, alpha value, and
q* score (Benjamini-Hochberg adjusted p value) for the 796 proteins
identified with 5 or more peptides.
Identification of dysregulated vitamin A networks in the
diabetic renal cortical proteome
After statistical analysis (fold change $1.5 and p#0.05 after
Benjamini-Hochberg adjustment) of the 796 proteins, 53 proteins
were identified as significantly dysregulated in renal cortex (these
proteins are highlighted in Table S2). The metabolite retinoic acid
was identified as a key signaling hub in one of the highest ranked
protein networks generated by Ingenuity Pathway Analysis (IPA)
(score=17) (Figure 1). Table 2 presents a list of the proteins identified
as significantly altered in fatty acid (the highest ranked dysregulated
protein network) and retinoic acid metabolism, and include alcohol
dehydrogenase (ADH1; downregulated 2.5 fold), and retinaldehyde
dehydrogenase 1 (ALDH1A1/RALDH1; upregulated 3 fold).
Alterations in Expression of Retinoid Metabolic Enzymes
In order to independently validate the mass spectrometry-
derived fold change in expression for these two enzymes, we next
used real time-PCR and immunoblotting to measure their
expression levels. Both mRNA (Figure 2A) and protein
(Figure 2B) levels of RALDH1 were increased significantly in
Table 1. Gravimetric and metabolic data for control and db/
db mice.
Measurement Control db/db
Body weight (g)
Initial 19633 3 62*
12 weeks 23634 2 62*
20 weeks 26624 8 61*
Blood glucose (mmol/l)
Initial 9.262.1 19.361.3 *
12 weeks 7.961.2 27.663.4 *
20 weeks 7.961.1 29.463.0 *
Values expressed as means6SD. Controls, n=10; db/db,n=1 0 .
Initial body weights correspond to the onset of hyperglycemia which occurs
around 6–8 weeks of age.
Significantly different from controls by Students t-test: * p,0.0001.
doi:10.1371/journal.pone.0011095.t001
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decreased significantly (Figure 2A). These results confirmed the
proteomics-based expression levels. Also, RALDH1 was upregu-
lated by a small (1.64 fold) but significant (p,0.05) amount in the
liver of db/db mice and in the renal cortex of 12 week old db/db
mice (data not shown). Using the LI-COR imaging system,
immunostaining for RALDH1 was located in the medullary
portion of the control mouse kidney (Figure 3A) with lesser
amounts present in the renal cortex near the surface of the kidney.
In the db/db mouse kidney, increased staining for RALDH1 was
evident in both renal medullary and cortical locations (Figure 3B).
At higher magnification, renal cortical RALDH1 was predomi-
nantly located in tubular epithelium of db/db mice (Figure 3D)
with little staining evident in diabetic glomeruli or in renal cortex
sampled from controls (Figure 3C). A low magnification image of a
coronal section through the mid-line of the kidney at the level of
the renal pelvis is shown in Figure S1. This image is a composite of
three Hematoxylin & Eosin stained images from the surface of the
kidney to the outer portion of the renal medulla.
Quantitative Measurement of Retinoids
Since enzymes involved in retinoid metabolism were dysregu-
lated in the db/db mouse kidney, we next measured retinoid levels
in selected tissues and plasma. Retinol (ROL) levels were increased
3.5 fold in plasma (Figure 4C, lower left panel) and 1.8 fold in
renal cortex (Figure 4A, lower left panel) of db/db vs control mice,
but decreased 0.64 fold in liver (Figure 4B, lower left panel). While
retinyl ester (RE) levels were unchanged in plasma and kidney, this
metabolite was significantly decreased in the liver (0.46control).
Retinaldehyde (RAL) was not measured in plasma and unchanged
in renal cortex, but was significantly decreased in diabetic liver
(0.36control). All-trans retinoic acid (atRA) was increased 2.3 fold
in diabetic vs control plasma, but was significantly decreased in
both liver and renal cortex compared to controls (0.76 and 0.536,
respectively). These results suggest a redistribution of all retinoid
metabolites from liver into plasma and kidney, yet substantial
decreases in atRA in renal cortex and liver despite elevated plasma
levels suggest decreased synthesis and/or increased metabolism of
atRA in these tissues.
Figure 1. Retinoic acid is a key signaling hub in the highest ranked network generated by IPA. Protein-protein associations are
indicated by edges containing single lines, whereas proteins that act upon another protein (controlling their expression) are indicated by
arrows. Nodes are represented by shapes and colors: Shapes indicate function: enzymes (diamond), transcription regulators (oval), nuclear
receptors (rectangle), cytokines (square), transporter (trapezoid), and ‘‘other’’ (circles). The red color indicates those proteins that are
significantly increased in abundance in the diabetic kidney while green indicates those that are significantly decreased. The intensity of the color
represents the degree of change. Abbreviations of proteins identified as significantly changed from the mass spectrometry dataset (indicated in
green and red) are: GGT1, gamma-glutamyltransferase 1; ACOX1, acyl-Coenzyme A oxidase 1; CYP4B1, cytochrome P450, family 4, subfamily B,
polypeptide 1; ADH1C, alcohol dehydrogenase 1C; CANX, calnexin; PAH, phenylalanine hydroxylase; EEF, elongation factor; GSTA5, glutathione
S-transferase alpha 5.
doi:10.1371/journal.pone.0011095.g001
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Since atRA levels were decreased despite increases in RALDH1
and unchanged levels of the intermediary substrate retinaldehyde,
we next used immunoblotting to probe expression levels of several
p450 enzymes previously reported to metabolize atRA, including
cyp2E1, cyp26A1, and DHRS9 (NADP-dependent retinol dehy-
drogenase/reductase). Figure 5A demonstrates that cyp2E1 was
weakly expressed in mouse renal cortex compared to its expression
level in mouse liver, increased in diabetic kidney (p,0.02), and
was unchanged in diabetic liver. CYP26A1 was weakly expressed
in both kidney and liver, and while its expression was decreased
slightly in the diabetic renal cortex, these differences were not
significant due to significant heterogeneity within both control and
diabetic animals. DHRS9 was undetectable in both kidney and
liver using whole tissue extracts with the antibody used (Novus
Biologicals; H00010170; data not shown).
Real time-PCR of retinoid binding proteins, atRA-linked
nuclear receptors, and target genes
Recent reports have suggested that suppression of obesity and
insulin resistance by atRA is largely mediated by PPARb/d [23],
and this effect is enhanced by activation of retinoic acid receptors
(RAR’s), while others have reported that atRA does not compete
with established PPARb/d agonists in ligand binding assays [24].
Since the potential interaction between atRA and PPARb/d
remains controversial, we measured the mRNA expression level of
this nuclear receptor as well as the retinoic acid receptor
transcription factors and the relevant binding proteins. Figure 6
indicates that message levels for cytosolic retinoic acid binding
protein (CRABP) and fatty acid binding protein (FABP) were
unchanged by diabetes in the renal cortex, but that substantially
more FABP message (mean DCT=8.9) was present in the renal
cortex than CRABP message (mean DCT=14.5). PPARb/d also
was abundant in the control renal cortex (mean DCT=6.2) and
was significantly decreased 1.9 fold in diabetic renal cortex (mean
DCT=7.1). While RARa was increased 1.6 fold, and RARb
decreased 2.2 fold, these changes were not significant due to
substantial animal variability in the control mice.
Discussion
We used a quantitative, stable isotope labeling approach
combined with multidimensional LC-MS/MS to identify proteins
differentially expressed in the renal cortex of the db/db mouse, a
widely used model of type 2 diabetes. We then used IPA to map
the significantly altered proteins identified with this experimental
approach to protein pathways and networks dysregulated by
diabetes, and bioinformatics to understand the relationships of
these altered proteins in these pathways and networks. As a result,
we identified a high ranking network containing the vitamin A
metabolite retinoic acid as a significant signaling hub.
Retinoic acid is generated from retinol following the rate
limiting step of retinaldehyde formation. Numerous dehydroge-
nases contributing to the metabolism of these retinoids have been
reported, and generally fall into three major families: alcohol
dehydrogenase (ADH) or short-chain dehydrogenase/reductase
(SDR) enzymes that catalyze the reversible oxidation/reduction of
retinol and retinaldehyde, and aldehyde dehydrogenases (ALDH)
that catalyze the oxidation of retinaldehyde to retinoic acid
[16,36]. We identified ADH1 as being significantly downregulated
in the renal cortex of db/db mice using quantitative mass
spectrometry and supported this finding with real-time PCR. We
also identified RALDH1 as being significantly upregulated, which
was confirmed by real-time PCR, Western blotting, and
immunohistochemistry. This finding is in agreement with a trend
towards upregulation of RALDH1 in adipose tissue of ob/ob mice
[37]. We also showed that RALDH1 was upregulated by a small
but significant amount in the liver of db/db mice.
The role of ADH in the physiological generation of retinalde-
hyde remains controversial. Although some ADH convert retinol
into retinaldehyde in vitro, these enzymes do not recognize the
physiological form of retinol (holo-CRBPI) as substrate [38].
ADH1, and to a lesser extent ADH3, but not ADH4, convert high
doses of retinol (50 mg/kg) into RA in vivo [39,40], suggesting that
pathological retinol doses can overwhelm homeostasis mechanisms
and retinoid binding-protein capacities. Importantly, there are no
reports demonstrating that overexpression of ADH enhances
conversion of retinol into atRA, or that reduced ADH expression
Table 2. Selected list of proteins significantly altered by diabetes involved in fatty acid and retinoic acid metabolism.
Gene symbol UniProt Accession Entrez gene name Fold change q*
{
ALDH1A1 P24549 aldehyde dehydrogenase 1 family, member A1 2.99 5.42E-03
MCAT Q8R3F5 malonyl CoA:ACP acyltransferase (mitochondrial) 2.09 1.02E-02
ACSL1 P41216 acyl-CoA synthetase long-chain family member 1 2.06 3.22E-02
ACOT1 O55137 acyl-CoA thioesterase 1 1.55 3.35E-02
CYB5A P56395 cytochrome b5 type A (microsomal) 21.54 4.42E-02
ACOX1 Q9R0H0 acyl-Coenzyme A oxidase 1, palmitoyl 21.59 3.05E-06
ACSM1 Q91VA0 acyl-CoA synthetase medium-chain family member 1 21.64 1.76E-03
APOA1 Q00623 apolipoprotein A–I 21.67 1.67E-04
GGT1 Q60928 gamma-glutamyltransferase 1 21.67 7.06E-04
CROT Q9DC50 carnitine O-octanoyltransferase 21.93 2.88E-07
ALDH3A2 P47740 aldehyde dehydrogenase 3 family, member A2 22.05 2.85E-04
ACSM3 Q3UNX5 acyl-CoA synthetase medium-chain family member 3 22.14 4.73E-03
UGT2B17 P17717 UDP glucuronosyltransferase 2 family, polypeptide B17 22.23 5.19E-03
ADH1C P00329 Alcohol dehydrogenase 1C (class 1) 22.49 5.11E-12
Data are sorted by the fold change score. Two highlighted proteins represent key enzymes in retinol metabolism to retinoic acid.
{q* represents the False Discovery Rate.
doi:10.1371/journal.pone.0011095.t002
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retinol activation. The observation in this study that retinaldehyde
levels remained unchanged in the kidney despite significant
decreases in ADH suggests that ADH is not responsible for the
generation of retinaldehyde in the diabetic mouse kidney. The
possibility that the microsomal SDRs may be the physiological
converters of retinol to retinaldehyde in the kidney remains
speculative at this time.
Despite .3 fold increases in plasma retinol levels and renal
RALDH1 levels, we found that retinaldehyde was unchanged and
atRA was significantly decreased in the diabetic renal cortex. The
decrease in renal atRA may be due to decreased synthesis despite
elevated RALDH1 levels and/or increased metabolism and
clearance of retinoic acid. Alternatively, the decreased atRA
may have caused a compensatory increase in RALDH1 since
previous work has shown a negative feedback inhibition by atRA
on the expression of RALDH1 [41–43]. Previous clinical and
animal studies have focused primarily on plasma concentrations of
retinol and found varying correlations in type 2 diabetes while
demonstrating decreases in type 1 diabetes [44–48]. Our reported
increase in plasma retinol in this model of type 2 diabetes is in
contrast to the type 1 diabetes data, but is consistent with previous
reports of diabetes-induced increases in RBP4, a retinol-binding
protein which may be a biomarker of type 2 diabetes and insulin
resistance [17]. Our finding that retinol, retinol esters, and
retinaldehyde were significantly decreased in the liver suggests a
redistribution of retinoids from liver and adipose stores (data not
shown) accompanied by an increase in plasma retinoids in type 2
diabetes, and further suggests that simply measuring plasma
retinol levels provides an incomplete understanding of altered
vitamin A metabolism in diabetes. The implication(s) of this
diabetes-induced redistribution of retinoids from liver, and their
relevance to the progression of diabetic renal complications in this
Figure 2. Real time-PCR and western blot of RALDH1
(ALDH1A1) and real time-PCR of ADH. Real time-PCR was analyzed
using the DCT method and results are scaled to the mean control values
6SE (n=7). Western blots were performed in duplicate and normalized
to b-actin (n=7) and results are represented as mean6SE. A. RNA was
extracted from 50 mg of kidney cortical tissue and cDNA synthesis
performed according to the manufacturer’s instructions. Relative
quantification of RALDH1 and ADH mRNA was performed using a
MyiQ Single-Color Real-Time PCR Detection System. Control (n=4) and
diabetic (n=7) results are normalized to the expression level of
cyclophilin within each animal, and then plotted as fold change
compared to the average control value. B. RALDH1 Western blots. Total
tissue extracts were prepared from renal cortex of 3-month diabetic and
age-matched control mouse kidneys. An equal amount of protein
(50 mg/lane) was used for all animals, and representative control (lanes
1–4) and db/db (lanes 5–8) Western blots are shown. C. Densitometric
quantification of RALDH1 for 7 control and 7 diabetic mice. Results are
expressed as a mean and SD of the control and diabetic band intensities
after normalization to b actin in each lane. Student’s t-test: *p,0.005;
{p,0.001;
{p,0.01.
doi:10.1371/journal.pone.0011095.g002
Figure 3. Immunohistochemical staining of RALDH1. Represen-
tative 5 mm formalin-fixed sections of kidney are shown from control
(panels A and C) and db/db (panels B and D) mice. Panels A and B are
low magnification images of the entire kidney section scanned using
the LI-COR Bioscience Odyssey
TM Imaging System while higher power
confocal images are shown in Panels C and D. Negative controls
included omitting the primary antibody, rabbit monoclonal anti-
RALDH1 from Novus Biologicals (data not shown). Asterisks indicate
glomeruli. Magnification for panels C and D, 3006.
doi:10.1371/journal.pone.0011095.g003
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PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11095Figure 4. Quantification of retinoids extracted from tissue and plasma samples. Retinoids were quantified by LC/MS/MS as described
[18,34], while retinol and retinyl ester were quantified by HPLC/UV as described [35]. Tissue retinoids are expressed as mol/g tissue and plasma
retinoids are expressed as mol/mL plasma. Student’s t-test: *, p,0.05;
{p,0.005;
{p,0.0001.
doi:10.1371/journal.pone.0011095.g004
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results are similar to previous studies of chronic ethanol
intoxication where similar changes in retinoid distribution were
reported to cause hepatic steatosis, fibrosis, and increased risk of
hepatocellular carcinoma [49]. This also provides biological
plausibility into the increased risk of hepatocellular carcinoma in
patients with diabetes according to cohort studies [50]. Impor-
tantly, tissue atRA levels, despite varying plasma levels, are
reduced in this animal model, suggesting that, at the site of
retinoid function, there is the potential for reduced activity. Our
observation of decreased tissue atRA despite increased plasma
atRA is similar to the state of retinoic acid resistance seen in
patients treated with atRA for promyelocytic leukemia. The
retinoic acid resistance is believed to be caused by an increase in
catabolism of atRA in tissues [51]. This observation may explain
the failure of clinical trials utilizing carotenoids and/or retinoids
for the prevention of cancer and cardiovascular disease [52,53].
Despite evidence supporting the use of retinoic acid in the
treatment of cancers, randomized controlled trials have not
established efficacy and are not routinely used in clinical practice
(with the notable exception of promyelocytic leukemia), and our
data would suggest that the strategy of administering biologically
inactive retinoids for prevention of disease as attempted in
previous trials is unsuccessful because tissue metabolism dysreg-
ulation of atRA is causal for disease and not plasma and stored
atRA precursors.
Given the redundancy in enzymes responsible for the
generation and metabolism of retinoic acid, it is difficult to
completely elucidate the pathophysiological mechanism responsi-
ble for the altered atRA levels in type 2 diabetes. However, our
finding that diabetes increased renal cortical levels of CYP2E1 is
similar to recent observations in streptozotocin-diabetic rats
[20,54], and offers a potential mechanism for increased metab-
olism of atRA. CYP2E1 is a classical ethanol-inducible P450
enzyme well known to metabolize fatty acids, lipid hydroperox-
ides, and ketone bodies [55] as well as atRA [49]. Importantly, it
has been implicated in the generation of intramitochondrial
reactive oxygen species [20,56]. The diabetes-induced changes in
this enzyme were significant but relatively small, and numerous
other enzymes have been implicated in RA metabolism, including
Figure 5. Western immunoblots of CYP2E1 and CYP26A1. Total tissue extracts were prepared from renal cortex and liver of 3-month diabetic
and age-matched control mouse kidneys. An equal amount of protein (50 mg/lane) was used for all animals, and representative control (lanes 1–4)
and db/db (lanes 5–8) tissue extracts are shown on the left. Densitometric quantitation of 7 control and 7 db/db kidneys and livers are shown on the
right. Due to group differences in the expression level of b-actin caused by diabetes, results were not normalized to the loading control. Student’s t-
test: * p,0.02.
doi:10.1371/journal.pone.0011095.g005
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alterations of retinoic concentrations in non-retinoid toxicity states
[57]. Nevertheless, similarities between ethanol-induced increased
CYP2E1 and fatty liver damage and nonalcoholic-induced liver
steatohepatitis in diabetes suggest common mechanisms involving
CYP2E1 and atRA.
atRA exerts many of its biological activities by activating specific
members of the nuclear hormone receptor superfamily of
transcription factors. In addition to activating RAR, retinoic acid
has been shown to be a ligand for the nuclear receptor PPARb/d
[22,58], although this remains controversial [24]. Recently, it was
shown that there is a decrease in PPARb/d in adipose tissue of
dietary obese mice [23]. Treatment with atRA restored this
change, induced weight loss, and improved insulin responsiveness,
suggesting that suppression of obesity and insulin resistance by
atRA is largely mediated by PPARb/d. Similarly, we show
decreases in PPARb/d mRNA expression and atRA in the kidney
of db/db mice. The decrease in PPARb/d message is in contrast to
PPARa, which we have shown to be increased in the kidney of db/
db mice using proteomics techniques [59]. In that study, which
used two dimensional gel electrophoresis and spot picking for mass
spectrometry, we did not identify RALDH1 as significantly
dysregulated and the importance of altered vitamin A metabolism
was not appreciated. PPARa was identified as a significant hub in
a high-ranking network generated by Ingenuity Pathways Analysis
and confirmed by other investigators as significantly increased
[60].
It previously has been reported that the partitioning of RAR
and PPARb/d within cells is regulated by two members of the
intracellular lipid-binding proteins – cellular RA-binding protein
(CRABP) and one of the nine isotypes of fatty acid-binding protein
(FABP-5). CRABP-2 shuttles RA to the RARs [61], while FABP-5
shuttles RA to PPARb/d [58], thus determining the spectrum of
RA genes that are activated. While we did not demonstrate
significant changes in either CRABP-2 or FABP-5 message in
diabetic versus control kidneys, we did observe significantly more
message for FABP-5 than CRABP-2. We reported significant
decreases in atRA and in PPARb/d message, suggesting that genes
activated by this signaling axis are impaired in the renal cortex of
type 2 diabetes. Consistent with this suggestion was the
observation that the PPARb/d-regulated protein, peroxisomal
D3,D2-enoyl-CoA isomerase (PECI), was decreased in our
proteomics dataset (21.5 FC, BH,0.05) and confirmed by PCR
(21.9 FC, p,0.03) (data not shown). Our results are consistent
with a recent report that renal expression of PPARb/d was
significantly suppressed in animal models of type 1 diabetes [62].
In that study, it was hypothesized that reduced PPARb/d
expression contributed to renal lipotoxicity secondary to reduced
fatty acid oxidation. While we can associate changes in atRA levels
with alterations in PPARb/d mRNA and most likely activity, we
could not establish significant changes in the mRNA levels of
FABP-5, CRABP-2, RARa, or RARb. It therefore remains a
question as to how the alterations in atRA levels modulate RAR
activity. Regardless of the mechanism, atRA treatment is generally
associated with a reduction of renal inflammation [19,63], and
therefore makes the use of retinoic acid metabolism blocking
agents (RAMBA) a potential novel therapy for the treatment of
diabetic nephropathy in which inflammation is a key contributor
to the pathogenesis.
In conclusion, we have used a non-gel-based,
18O stable isotope
labeling approach combined with 2D LC-MS/MS and bioinfor-
matics to identify significant changes in protein expression, and to
map these altered proteins to novel protein pathways and networks
perturbed by diabetes in the renal cortex of the db/db mouse. This
approach led to the discovery of decreased renal cortical levels of
atRA in the diabetic mouse kidney. The pathophysiological
mechanism(s) responsible for the decreased atRA remains to be
elucidated at the cellular and molecular level. Likewise, potential
causal links between decreased renal cortical atRA levels and
progression of diabetic nephropathy and development of renal
inflammation remain to be explored. Nevertheless, our observa-
tions provide novel insights into potential links between altered
lipid metabolism and other gene networks controlled by retinoic
acid in the diabetic kidney, and demonstrate the utility of using
systems biology to gain new insights into diabetic nephropathy.
The redistribution of retinoids observed in this model of type 2
diabetes suggests a new pathophysiological mechanism for which
normalization of these changes may provide a novel therapy for
both hepatic steatosis and diabetic renal complications.
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